Analysts expect CorMedix Inc (NASDAQ:CRMD) to announce sales of $90,000.00 for the current fiscal quarter, according to Zacks. Two analysts have made estimates for CorMedix’s earnings. The lowest sales estimate is $20,000.00 and the highest is $150,000.00. CorMedix reported sales of $30,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 200%. The company is scheduled to report its next earnings report on Thursday, March 12th.
According to Zacks, analysts expect that CorMedix will report full-year sales of $460,000.00 for the current fiscal year, with estimates ranging from $430,000.00 to $490,000.00. For the next fiscal year, analysts anticipate that the business will post sales of $12.28 million, with estimates ranging from $9.89 million to $14.67 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow CorMedix.
CRMD stock opened at $5.56 on Monday. The firm has a 50 day moving average price of $5.85 and a 200-day moving average price of $7.46. CorMedix has a 52-week low of $4.20 and a 52-week high of $13.70.
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Recommended Story: Why do companies issue monthly dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.